Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

Intelligent Bio Solutions (Nasdaq: INBS) announced on March 26, 2026 that it received European Patent EP3752831, its eighth European patent.

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) announced on March 26, 2026 that it received European Patent EP3752831, its eighth European patent.

The patent protects an advance that correlates fingerprint chemical findings with fingerprint deposition volume, strengthening the company’s European IP around fingerprint sweat drug screening, lateral flow analysis, sample cartridges, and test strip readers.

Positive

• Eighth European patent granted (EP3752831) strengthening IP footprint
• Patent protects correlation of chemical analysis with fingerprint deposition volume
• Portfolio breadth now covers lateral flow analysis, cartridges, and test strip reader

Negative

• None.

Argus Mar 26 session

+1.49% close to close Open Argus

Details

News Market Reaction – INBS

On Mar 26, the day this news came out, INBS closed 1.49% above the previous close.

Data tracked by StockTitan Argus for the Mar 26 session.

Market Context

This announcement adds a newly granted European patent (EP3752831) to INBS’s fingerprint sweat drug ...

Analysis

This announcement adds a newly granted European patent (EP3752831) to INBS’s fingerprint sweat drug testing IP, bringing the total to 8 European patents covering lateral flow analysis, cartridges, and readers. It follows recent revenue growth, clinical progress toward an FDA 510(k), and new commercial partnerships. Investors may watch how the enlarged IP portfolio supports adoption while considering financing needs, the active S-3 resale registration, ATM capacity, and disclosed going-concern risks in recent SEC filings.

Key Figures

European patents: 8 patents

European patents

8 patents

Total European patents covering fingerprint sweat drug testing technology

Historical Context

5 past events · Latest: Feb 25

5 events

1. Feb 25

   Manufacturing scale-up

   24h Move

   -4.3%

   First shipment of readers from new partner, boosting capacity and margins.

2. Feb 24

   Commercial partnership

   24h Move

   -2.6%

   Bouygues UK partnership deploying fingerprint drug screening across 13 sites.

3. Feb 12

   Earnings report

   24h Move

   -6.7%

   Record Q2 revenue growth of 48% YoY and improved gross margin to 49%.

4. Feb 05

   Earnings pre-announcement

   24h Move

   -9.1%

   Preliminary guidance for ~48% Q2 revenue growth and ~$2.01M H1 revenue.

5. Jan 28

   Clinical trial start

   24h Move

   +2.9%

   Initiation of clinical studies supporting FDA 510(k) codeine detection submission.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intellectual property, lateral flow, sample collection cartridges, lateral flow test strip reader

4 terms

intellectual property regulatory

"reinforces Company's European intellectual property protection"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

lateral flow medical

"portfolio now encompasses multiple aspects of its screening system, including lateral flow fingerprint analysis"

A lateral flow test is a small, disposable diagnostic device that detects the presence of a substance (like a virus protein or antibody) in a liquid sample by letting it flow across a paper strip with embedded reagents, similar to a home pregnancy test. Investors care because these tests are cheap, fast, and easy to scale and distribute, making them a major revenue source during health events, subject to regulatory approval, manufacturing capacity, and changing demand.

sample collection cartridges technical

"including lateral flow fingerprint analysis, sample collection cartridges, and lateral flow test strip reader"

A sample collection cartridge is a small, often single-use container or module used to capture and preserve blood, saliva, swabs, or other biological material for laboratory tests or diagnostic machines. Think of it like a camera film cartridge that safely holds and transports the material until a machine reads it. Investors care because cartridge quality and supply affect test accuracy, regulatory approval, repeat sales, manufacturing costs, and a company’s ability to scale diagnostic services.

lateral flow test strip reader technical

"sample collection cartridges, and lateral flow test strip reader"

A lateral flow test strip reader is a small device or instrument that digitally scans and interprets the results of paper-based rapid diagnostic tests (the kind with visible lines, like a pregnancy or COVID rapid test). It turns a visual, sometimes subjective result into a standardized digital readout and record, improving speed, accuracy and data capture. Investors care because readers can increase test reliability, enable automated reporting, support higher-volume use, and drive recurring revenues through consumables, software and regulatory approvals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent strengthens competitive position in European drug screening market and reinforces Company's European intellectual property protection

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technology.

The newly granted patent protects a key advancement in how the Company's technology analyzes substances detected in fingerprint sweat by correlating chemical findings with the volume of fingerprint residue deposited during sample collection. By contextualizing chemical analysis with deposition volume, the technology improves the interpretation of detected substances and strengthens the robustness of the testing process. This innovation adds another layer of sophistication to INBS' testing methodology. The Company's growing European IP portfolio now encompasses multiple aspects of its screening system, including lateral flow fingerprint analysis, sample collection cartridges, and lateral flow test strip reader.

"The grant of our eighth European patent reflects the depth of innovation embedded in our fingerprint sweat drug testing technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Each patent we secure reinforces our market position and protects the scientific breakthroughs that make our non-invasive approach a compelling alternative to traditional drug screening methods."

INBS' Intelligent Fingerprinting Drug Testing Solution offers organizations across safety-critical sectors a faster, more dignified alternative to conventional testing methods. By analyzing fingerprint sweat for the presence of common substances of abuse, the technology eliminates many of the logistical and privacy concerns associated with traditional sample collection while delivering rapid, reliable results.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Intelligent Bio Solutions (INBS) announce on March 26, 2026 about EP3752831?

They announced the grant of European Patent EP3752831, their eighth European patent. According to the company, the patent protects correlating chemical findings with fingerprint deposition volume to improve interpretation and robustness of fingerprint sweat drug testing.

How does the new EP3752831 patent affect INBS fingerprint sweat drug testing technology (INBS)?

The patent adds protection for correlating residue volume with chemical results, improving analysis context. According to the company, this enhances result interpretation and strengthens the testing methodology’s reliability for safety-critical screening.

Which parts of INBS technology does the company's growing European IP portfolio cover (INBS)?

The portfolio covers lateral flow fingerprint analysis, sample collection cartridges, and the lateral flow test strip reader. According to the company, EP3752831 complements these existing IP elements across its screening system.

Why is the EP3752831 grant important for Intelligent Bio Solutions' market position (INBS)?

The grant reinforces European intellectual property protection and competitive positioning in drug screening. According to the company, each patent strengthens market position and protects scientific advances in their non-invasive approach.

Will the EP3752831 patent change how organizations use INBS fingerprint testing (INBS)?

The patent itself secures an analytical improvement rather than operational changes. According to the company, it supports more robust interpretation of fingerprint sweat results, potentially increasing confidence among users in safety-critical sectors.